Acasti Pharma Inc. (ACST)
After hours:
| Previous Close | 0.9538 |
| Open | 1.0000 |
| Bid | 0.9300 x 4000 |
| Ask | 0.9700 x 1000 |
| Day's Range | 0.9003 - 1.0000 |
| 52 Week Range | 0.8200 - 5.4400 |
| Volume | |
| Avg. Volume | 143,251 |
| Market Cap | 42.539M |
| Beta (5Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints
Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3 remains on track to start before year-end A conference call to discuss the results scheduled for Wednesday May 18th at 1:00 PM Eastern Time LAVAL, Québec, May 18, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study
- ACCESSWIRE
Update: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th
LAVAL, QC / ACCESSWIRE / May 16, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq:ACST) and (TSX-V:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present at the Spring Into Action- Best Ideas Investor Conference, which is being held virtually May 16-20, 2022.
- ACCESSWIRE
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Spring into Action: VIRTUAL begins on Monday, May 16th, 2022, with a Biotech Discovery Day.
